Apr 13, 2026 · Buprenorphine extended-release injection is given subcutaneously (just under the skin). Sublocade and Brixadi can be given in the abdomen, thigh, buttock, or the back of the upper arm.

Mar 23, 2026 · Sublocade (buprenorphine) is an extended-release, once-monthly subcutaneous (under the skin) injection that steadily releases buprenorphine into your bloodstream for the treatment of …

Use of buprenorphine extended-release subcutaneous injection or buprenorphine subdermal implants is not recommended in patients with preexisting moderate to severe hepatic impairment since the …

The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use to treat moderate to severe opioid use disorder (OUD)

This guidance provides key information for prescribing and administering long-acting subcutaneous buprenorphine products to opioid dependent patients aged 16 years and over.

Buprenorphine Extended-Release Injection (Sublocade) Buprenorphine injections treat people with opioid use disorder by reducing their withdrawal symptoms and cravings for opioids. The most …

Nov 7, 2024 · Injectable Buprenorphine: Getting Started This resource guide provides basic information about the two extended-release injectable forms of buprenorphine (BUP-XR) – SublocadeTM and …

Buprenorphine can reduce cravings and block the rewarding effects of other opioids, which can help break the cycle of addiction. SUBLOCADE is an injection given by your treatment provider; it is not a …

May 6, 2025 · Sublocade (Buprenorphine Injection for Subcutaneous Use) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug …

Buprenorphine Subcutaneous Injection SA (BRIXADI)* Mini-Monograph Nov 2023 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives